Position in CRVS
as of Mar 31, 2026
· filed May 11, 2026
Position Value
$9,326,625
+$3,713,325 QoQ
Shares Held
637,500
-12.6% QoQ
Ownership
0.758%
of shares outstanding
% of Portfolio
4.03%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in CRVS Over Time
Shares Held
Position Value (USD)
Derivatives in CRVS
reported options exposure · as of Jun 30, 2025CallValue
$10,000
CallShares
2,500
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026DCF Advisers, LLC holds $55,575,072 across 20 Biotechnology names. CRVS ranks #2 (16.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ARGX |
Argenx SE
|
14,650 | $10,698,162 | |
| 2 | CRVS |
Corvus Pharmaceuticals, Inc.
This page
|
637,500 | $9,326,625 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
9,250 | $7,146,920 | |
| 4 | NAMS |
NewAmsterdam Pharma Co N.V.
|
160,600 | $5,140,806 | |
| 5 | IONS |
Ionis Pharmaceuticals Inc
|
56,000 | $4,205,040 | |
| 6 | INCY |
Incyte Corp
|
41,500 | $3,905,980 | |
| 7 | HELP |
Cybin Inc.
|
691,988 | $3,321,542 | |
| 8 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
7,000 | $3,125,780 |
All Filings in CRVS
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $9,326,625 | 637,500 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $5,613,300 | 729,000 | Shares | Sole | 2026-02-11 | |
| 2025-06-30 | $3,030,000 | 757,500 | Shares | Sole | 2025-08-12 | |
| 2025-06-30 | $10,000 | 2,500 | Call | Sole | 2025-08-12 | |
| 2025-03-31 | $1,272,000 | 400,000 | Shares | Sole | 2025-05-09 | |
| 2025-03-31 | $15,900 | 5,000 | Call | Sole | 2025-05-09 | |
| No filing history on record for this holder in this stock. | ||||||